ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. The company specialises in high quality medicines for the treatment of important diseases in the livestock sector. ECO Animal Health are dedicated to the research, development and marketing of strong brands, differentiated generics and innovative new solutions.

11 Nov 2026

European Marketing Authorisation Application for ECOVAXXIN® MG

ECO Animal Health Group has announced that it has submitted a Marketing Authorisation Application and supporting dossier to the European Medicines Agency (EMA) for ECOVAXXIN® MG, its live poultry vaccine targeting Mycoplasma gallisepticum.

ECOVAXXIN® MG is the second ‘late-stage’ vaccine product in ECO’s R&D pipeline submitted for EMA marketing authorisation. If approved, ECOVAXXIN® MG will extend ECO’s poultry vaccine offering alongside ECOVAXXIN® MS and complement Aivlosin®, the Group’s flagship, market-leading antibiotic for the treatment of respiratory and intestinal diseases in both pigs and poultry.

This latest development follows progress towards commercial launch in the EU of ECOVAXXIN® MS, the vaccine against Mycoplasma synoviae and the first of the portfolio of products under development, in July 2026.

The announcement of Interim Results on 30 November offers the opportunity to review our FY27 outlook; we maintain our Fair Value of 180p/share.

Download as a PDF file

Return to ECO Animal Health

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 3rd Floor, 80 Cheapside, London, EC2V 6EE